<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00697541</url>
  </required_header>
  <id_info>
    <org_study_id>COL-118-ROSE-202</org_study_id>
    <secondary_id>RD.06.SPR.18126</secondary_id>
    <nct_id>NCT00697541</nct_id>
  </id_info>
  <brief_title>Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%</brief_title>
  <official_title>A Phase II, Single-Center, Two-Way Crossover Relative Systemic Bioavailability Study of Col-118 Administered Topically as a 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2% Administered to the Eye in Subjects With Moderate to Severe Erythematous Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II systemic bioavailability crossover study to measure the exposure of Col-118 topical
      0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2%
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, randomized, 2-way crossover, safety, pharmacokinetic/-dynamic (PK/PD) study
      of 0.18% COL-118 facial gel and 0.2% brimonidine ophthalmic solution administered in male and
      female patients with moderate to severe erythematous rosacea.

      Twenty male and female subjects with moderate to severe erythematous rosacea will be
      randomized into 2 groups of 10 subjects.

      Each group will be randomized to receive 2 treatments (Treatments A and B, in Sequence 1: A/B
      or Sequence 2: B/A), as follows:

      Treatment A: One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine)
      administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the
      morning. 1 g of 0.18% COL-118 facial gel is reapplied once after four hours;

      Treatment B: One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate)
      administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg
      brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118
      facial gel vehicle (0.0 mg brimonidine) is administered topically.

      There will be at least a 1-day washout between dose administrations (Period 1 and Period 2).

      Blood samples for PK analysis of brimonidine levels will be collected at the following time
      points during Period 1 and Period 2: 0 Hour (prior to dose) and at 1, 2, 3, 4 (prior to 2nd
      dose), 5, 6, 7, and 8 hours post-dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Maximum Systemic Concentration of Brimonidine</measure>
    <time_frame>0 Hour (prior to dose) and at 1, 2, 3, 4, 5, 6, 7, and 8 hours post-morning dose</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC - Area Under the Curve of Brimonidine</measure>
    <time_frame>0 Hour (prior to dose) and at 1, 2, 3, 4, 5, 6, 7, and 8 hours post-morning dose</time_frame>
    <description>Area under the plasma concentration-time curve from 0 hour to the last measurable plasma concentration, calculated by the linear trapezoidal method
After two topical applications of 0.18% COL-118 facial gel, plasma levels of brimonidine for all subjects were below the LoQ (25 pg/mL), with the exception of one single outlier value.
Thus, no PK analysis could be performed for 0.18% COL-118 facial gel.
After ocular administration of 0.2% brimonidine tartrate ophthalmic solution, quantifiable plasma concentrations of brimonidine were observed in 11 of the 18 subjects who received the brimonidine tartrate ophthalmic solution. Brimonidine rapidly appeared in plasma The mean Cmax was not calculated because values were not quantifiable for 7 of 18 subjects The mean AUC0-t also was not calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax - Time to Maximum Plasma Concentration</measure>
    <time_frame>0 Hour (prior to dose) and at 1, 2, 3, 4, 5, 6, 7, and 8 hours post-morning dose</time_frame>
    <description>time to maximum plasma concentration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Erythematous Rosacea</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after four hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.18% COL-118 facial gel (1.8 mg brimonidine)</intervention_name>
    <description>One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours</description>
    <arm_group_label>A</arm_group_label>
    <other_name>brimonidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)</intervention_name>
    <description>One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>brimonidine tartrate/drop</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advanced Eye Relief</intervention_name>
    <description>One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COL-118 facial gel vehicle</intervention_name>
    <description>One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥18 years of age

          -  Clinical diagnosis of rosacea

          -  A score of ≥ 3 on the CEAS

          -  A score of ≥ 3 on the PSA

          -  IOP ≥ 10 mm Hg

          -  Non-pregnant and non-lactating females

        Exclusion Criteria:

          -  History of hypersensitivity or allergies to any ingredient of the study drugs, unless
             approved by the Investigator

          -  Use of brimonidine prescription medications within 14 days prior to Check-in

          -  Use of any over-the-counter (OTC), non-prescription preparations (including vitamins,
             minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days prior
             to Check-in, unless deemed acceptable by the Investigator

          -  Use of systemic or topical steroids applied to the face 14 days prior to Check in

          -  The use of any Rx or OTC products for the treatment of acne or rosacea within 14 days
             prior to check in

          -  The use of isotretinoin within 180 days prior to check in
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Leyden, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGL, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGL, Inc.</name>
      <address>
        <city>Broomall</city>
        <state>Pennsylvania</state>
        <zip>19008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2008</study_first_submitted>
  <study_first_submitted_qc>June 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2008</study_first_posted>
  <results_first_submitted>September 19, 2013</results_first_submitted>
  <results_first_submitted_qc>August 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 7, 2014</results_first_posted>
  <disposition_first_submitted>October 16, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>December 2, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 6, 2010</disposition_first_posted>
  <last_update_submitted>August 6, 2014</last_update_submitted>
  <last_update_submitted_qc>August 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>erythematous rosacea</keyword>
  <keyword>facial gel</keyword>
  <keyword>brimonidine</keyword>
  <keyword>ophthalmic solution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Seq1-facial Gel+Saline Drops,Then Vehicle+Brimonidine Drops</title>
          <description>One (1) gram of 0.18% COL-118 facial gel (1.8 mg brimonidine tartrate) administered topically plus 1 drop of Advanced Eye Relief™ (placebo ophthalmic solution) in each eye, once in the morning. One (1) gram of 0.18% COL-118 facial gel was to be reapplied once after 4 hours.
First intervention (1 day), washout (1 day), Second intervention (1 day)</description>
        </group>
        <group group_id="P2">
          <title>Seq2-vehicle+Brimonidine Drops,Then Facial Gel+Saline Drops</title>
          <description>One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
First intervention (1 day), washout (1 day), Second intervention (1 day)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Seq1-facial Gel+Saline Drops,Then Vehicle+Brimonidine Drops</title>
          <description>One (1) gram of 0.18% COL-118 facial gel (1.8 mg brimonidine tartrate) administered topically plus 1 drop of Advanced Eye Relief™ (placebo ophthalmic solution) in each eye, once in the morning. One (1) gram of 0.18% COL-118 facial gel was to be reapplied once after 4 hours.
First intervention (1 day), washout (1 day), Second intervention (1 day)</description>
        </group>
        <group group_id="B2">
          <title>Seq2-vehicle+Brimonidine Drops,Then Facial Gel+Saline Drops</title>
          <description>One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
First intervention (1 day), washout (1 day), Second intervention (1 day)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.0" spread="8.5"/>
                    <measurement group_id="B2" value="47.1" spread="6.7"/>
                    <measurement group_id="B3" value="45.1" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Systemic Concentration of Brimonidine</title>
        <description>Maximum observed plasma concentration</description>
        <time_frame>0 Hour (prior to dose) and at 1, 2, 3, 4, 5, 6, 7, and 8 hours post-morning dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - COL-118 Facial Gel + Saline Drops</title>
            <description>COL-118 facial gel + saline drops</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - Vehicle Gel + Brimonidine Drops</title>
            <description>Vehicle gel + brimonidine drops</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Systemic Concentration of Brimonidine</title>
          <description>Maximum observed plasma concentration</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">After application of Brimonidine 0.18% Gel, plasma levels of brimonidine for all subjects were below the limit of quantification (&lt; 25 pg/mL) with the exception of one single outlier value therefore no PK analysis could be performed.</measurement>
                    <measurement group_id="O2" value="NA" upper_limit="100">The mean Cmax was not calculated because values were not quantifiable for 7 of 18 subjects.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC - Area Under the Curve of Brimonidine</title>
        <description>Area under the plasma concentration-time curve from 0 hour to the last measurable plasma concentration, calculated by the linear trapezoidal method
After two topical applications of 0.18% COL-118 facial gel, plasma levels of brimonidine for all subjects were below the LoQ (25 pg/mL), with the exception of one single outlier value.
Thus, no PK analysis could be performed for 0.18% COL-118 facial gel.
After ocular administration of 0.2% brimonidine tartrate ophthalmic solution, quantifiable plasma concentrations of brimonidine were observed in 11 of the 18 subjects who received the brimonidine tartrate ophthalmic solution. Brimonidine rapidly appeared in plasma The mean Cmax was not calculated because values were not quantifiable for 7 of 18 subjects The mean AUC0-t also was not calculated.</description>
        <time_frame>0 Hour (prior to dose) and at 1, 2, 3, 4, 5, 6, 7, and 8 hours post-morning dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - COL-118 Gel + Saline Drops</title>
            <description>COL-118 gel + saline drops</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - Vehicle Gel + Brimonidine Drops</title>
            <description>Vehicle gel + brimonidine drops</description>
          </group>
        </group_list>
        <measure>
          <title>AUC - Area Under the Curve of Brimonidine</title>
          <description>Area under the plasma concentration-time curve from 0 hour to the last measurable plasma concentration, calculated by the linear trapezoidal method
After two topical applications of 0.18% COL-118 facial gel, plasma levels of brimonidine for all subjects were below the LoQ (25 pg/mL), with the exception of one single outlier value.
Thus, no PK analysis could be performed for 0.18% COL-118 facial gel.
After ocular administration of 0.2% brimonidine tartrate ophthalmic solution, quantifiable plasma concentrations of brimonidine were observed in 11 of the 18 subjects who received the brimonidine tartrate ophthalmic solution. Brimonidine rapidly appeared in plasma The mean Cmax was not calculated because values were not quantifiable for 7 of 18 subjects The mean AUC0-t also was not calculated.</description>
          <units>pg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">After application of Brimonidine 0.18% Gel, plasma levels of brimonidine for all subjects were below the limit of quantification (&lt; 25 pg/mL) with the exception of one single outlier value therefore no PK analysis could be performed.</measurement>
                    <measurement group_id="O2" value="NA" upper_limit="471">The mean AUC was not calculated because values were not quantifiable for 9 of 18 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax - Time to Maximum Plasma Concentration</title>
        <description>time to maximum plasma concentration</description>
        <time_frame>0 Hour (prior to dose) and at 1, 2, 3, 4, 5, 6, 7, and 8 hours post-morning dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - COL-118 Facial Gel + Saline Drops</title>
            <description>COL-118 facial gel + saline drops</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - Vehicle Gel + Brimonidine Drops</title>
            <description>Vehicle gel + brimonidine drops</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax - Time to Maximum Plasma Concentration</title>
          <description>time to maximum plasma concentration</description>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">After application of Brimonidine 0.18% Gel, plasma levels of brimonidine for all subjects were below the limit of quantification (&lt; 25 pg/mL) with the exception of one single outlier value therefore no PK analysis could be performed.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0.933" upper_limit="4.07">After ocular administration of the 0.2% brimonidine tartrate ophthalmic solution, quantifiable plasma concentrations were observed in 11 of the 18 subjects, therefore Tmax Mean is NA.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>COL-118 gel + saline drops</description>
        </group>
        <group group_id="E2">
          <title>Treatment B</title>
          <description>Vehicle gel + brimonidine drops</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pharyngolagyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Graeber, MD</name_or_title>
      <organization>Galderma</organization>
      <phone>609-860-8201</phone>
      <email>michael.graeber@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

